These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

607 related items for PubMed ID: 19139988

  • 1. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
    Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R, Meyer WG, O'Shaughnessy JA.
    Breast Cancer Res Treat; 2009 Aug; 116(3):521-7. PubMed ID: 19139988
    [Abstract] [Full Text] [Related]

  • 2. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J.
    J Clin Oncol; 2006 Aug 20; 24(24):3991-6. PubMed ID: 16921052
    [Abstract] [Full Text] [Related]

  • 3. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
    Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB.
    Breast J; 2006 Aug 20; 12(2):114-22. PubMed ID: 16509835
    [Abstract] [Full Text] [Related]

  • 4. Does hormonal therapy decrease tamoxifen associated hot flashes?
    Barton DL, Loprinzi CL.
    Breast Cancer Res Treat; 2009 Aug 20; 116(3):529-30. PubMed ID: 19205876
    [No Abstract] [Full Text] [Related]

  • 5. Type of menopause, patterns of hormone therapy use, and hot flashes.
    Gallicchio L, Whiteman MK, Tomic D, Miller KP, Langenberg P, Flaws JA.
    Fertil Steril; 2006 May 20; 85(5):1432-40. PubMed ID: 16566933
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial.
    Walker EM, Rodriguez AI, Kohn B, Ball RM, Pegg J, Pocock JR, Nunez R, Peterson E, Jakary S, Levine RA.
    J Clin Oncol; 2010 Feb 01; 28(4):634-40. PubMed ID: 20038728
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy.
    Mousa NA, Crystal P, Wolfman WL, Bedaiwy MA, Casper RF.
    Menopause; 2008 Feb 01; 15(5):875-84. PubMed ID: 18480735
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk.
    Col NF, Chlebowski RT.
    Menopause; 2008 Feb 01; 15(4 Suppl):804-9. PubMed ID: 18596602
    [Abstract] [Full Text] [Related]

  • 13. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Abdulhaq H, Geyer C.
    Am J Clin Oncol; 2008 Dec 01; 31(6):595-605. PubMed ID: 19060594
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term follow-up of acupuncture and hormone therapy on hot flushes in women with breast cancer: a prospective, randomized, controlled multicenter trial.
    Frisk J, Carlhäll S, Källström AC, Lindh-Astrand L, Malmström A, Hammar M.
    Climacteric; 2008 Apr 01; 11(2):166-74. PubMed ID: 18365859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.